Neratinib plus fulvestrant in ERBB2-mutant, HER2-non-amplified, estrogen receptor (ER)-positive, metastatic breast cancer (MBC): Preliminary analysis from the phase II SUMMIT trial

被引：7
|
作者：
Hyman, D.
Piha-Paul, S.
Saura, C.
Arteaga, C.
Mayer, I.
Shapiro, G.
Loi, S.
Lalani, A.
Xu, F.
Cutler, R.
Butturini, A.
Bryce, R.
Meric-Bernstam, F.
Baselga, J.
Solit, D.
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] MD Anderson Canc Ctr, Houston, TX USA
[3] Vall Hebron Univ Hosp, VHIO, Barcelona, Spain
[4] Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA
[5] Dana Farber Canc Inst, Boston, MA 02215 USA
[6] Peter MacCallum Canc Inst, 481 Little Lonsdale St, Melbourne, Vic 3000, Australia
[7] Puma Biotechnol Inc, Los Angeles, CA USA
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-PD2-08
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD2-08
引用
收藏
页数：2
相关论文
共 50 条
  • [1] OVERCOMING HER2/ESTROGEN RECEPTOR (ER) CROSSTALK: NERATINIB ± FULVESTRANT IN ER+HER2-MUTANT METASTATIC BREAST CANCER (MBC) IN THE PHASE II SUMMIT TRIAL.
    Beer, Hannah
    Cutler, Rich
    Piha-Paul, Sarina
    Saura, Cristina
    Lalani, Alshad
    Hyman, David
    ONCOLOGY NURSING FORUM, 2017, 44 (02)
  • [2] Update on the phase II SUMMIT trial: Neratinib plus fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer
    Smyth, L. M.
    Saura, C.
    Piha-Paul, S. A.
    Lu, J.
    Mayer, I. A.
    Brufksy, A. M.
    Spanggaard, I.
    Arnedos, M.
    Cutler, R. E.
    Hyman, D. M.
    ANNALS OF ONCOLOGY, 2019, 30 : 10 - 11
  • [3] Neratinib plus trastuzumab plus fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer: Updated results from the phase 2 SUMMIT 'basket' trial
    Wildiers, Hans
    Boni, Valentina
    Saura, Cristina
    Oliveira, Mafalda
    Jhaveri, Komal
    Won, Helen
    Bidard, Francois-Clement
    Brufsky, Adam M.
    Burkard, Mark E.
    Cervantes, Andres
    Fernandez-Martos, Carlos
    Haley, Barbara
    Loi, Sherene
    Spanggaard, Iben
    Panni, Stefano
    Lu, Janice
    Dujka, Melanie E.
    Xu, Feng
    Macia, Sonia
    Eli, Lisa D.
    Lalani, Alshad S.
    Piha-Paul, Sarina
    Meric-Bernstam, Funda
    Solit, David B.
    Hyman, David M.
    CANCER RESEARCH, 2020, 80 (04)
  • [4] Latest findings from the breast cancer cohort in SUMMIT - a phase 2 'basket' trial of neratinib plus trastuzumab plus fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer
    Jhaveri, Komal
    Saura, Cristina
    Guerrero-Zotano, Angel
    Spanggaard, Iben
    Bidard, Francois-Clement
    Goldman, Jonathan W.
    Garcia-Saenz, Jose A.
    Cervantes, Andres
    Boni, Valentina
    Crown, John
    Brufsky, Adam
    Loi, Sherene
    Haley, Barbara
    Mayer, Ingrid A.
    Chia, Stephen
    Lu, Janice
    Waisman, James
    Ben-Baruch, Noa Efrat
    Burkard, Mark E.
    Suga, Jennifer M.
    Gonzalez-Cortijo, Lucia
    Perrucci, Bruno
    Xu, Feng
    Wong, Sofia
    Zhang, Jie
    Eli, Lisa D.
    Lalani, Alshad S.
    Wildiers, Hans
    CANCER RESEARCH, 2021, 81 (04)
  • [5] Neratinib plus fulvestrant plus trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial
    Jhaveri, K.
    Eli, L. D.
    Wildiers, H.
    Hurvitz, S. A.
    Guerrero-Zotano, A.
    Unni, N.
    Brufsky, A.
    Park, H.
    Waisman, J.
    Yang, E. S.
    Spanggaard, I.
    Reid, S.
    Burkard, M. E.
    Vinayak, S.
    Prat, A.
    Arnedos, M.
    Bidard, F. -C.
    Loi, S.
    Crown, J.
    Bhave, M.
    Piha-Paul, S. A.
    Suga, J. M.
    Chia, S.
    Saura, C.
    Garcia-Saenz, J. a.
    Gambardella, V.
    de Miguel, M. J.
    Gal-Yam, E. N.
    Raphael, A.
    Stemmer, S. M.
    Ma, C.
    Hanker, A. B.
    Ye, D.
    Goldman, J. W.
    Bose, R.
    Peterson, L.
    Bell, J. S. K.
    Frazier, A.
    Diprimeo, D.
    Wong, A.
    Arteaga, C. L.
    Solit, D. B.
    ANNALS OF ONCOLOGY, 2023, 34 (10) : 885 - 898
  • [6] Cell-free DNA sequencing in ERBB2-mutant breast cancer patients treated with neratinib and fulvestrant: Exploratory analysis from the Phase 2 SUMMIT 'basket' trial
    Schram, Alison M.
    Selcuklu, S. Duygu
    Nagy, Rebecca J.
    Smyth, Lillian M.
    Eli, Lisa D.
    Cutler, Richard E.
    Lalani, Alshad S.
    Hyman, David M.
    Lanman, Richard B.
    CANCER RESEARCH, 2018, 78 (13)
  • [7] Phase II trial of neratinib for HER2 mutated, non-amplified metastatic breast cancer (HER2mut MBC).
    Ma, Cynthia X.
    Bose, Ron
    Gao, Feng
    Freedman, Rachel A.
    Pegram, Mark D.
    Blackwell, Kimberly
    Bedard, Philippe L.
    Hayes, Daniel F.
    Goetz, Matthew P.
    Niravath, Polly Ann
    Russell, Christy Ann
    Tripathy, Debu
    Cobleigh, Melody A.
    Forero, Andres
    Pluard, Timothy J.
    Anders, Carey K.
    Bumb, Caroline
    Naughton, Michael
    Al-Kateb, Hussam
    Ellis, Matthew James
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] Neratinib plus fulvestrant plus trastzuzumab (N plus F plus T) for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial.
    Jhaveri, Komal L.
    Goldman, Jonathan W.
    Hurvitz, Sara A.
    Guerrero-Zotano, Angel
    Unni, Nisha
    Brufsky, Adam
    Park, Haeseong
    Waisman, James Ross
    Yang, Eddy Shih-Hsin
    Spanggaard, Iben
    Reid, Sonya A.
    Burkard, Mark E.
    Prat, Aleix
    Loi, Sherene
    Crown, John
    Hanker, Ariella
    Ma, Cynthia X.
    Bose, Ron
    Eli, Lisa DeFazio
    Wildiers, Hans
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] A phase II trial of neratinib (NER) or NER plus fulvestrant (FUL) (N+F) in HER2 mutant, non-amplified (HER2mut) metastatic breast cancer (MBC): Part II of MutHER.
    Ma, Cynthia X.
    Luo, Jingqin
    Freedman, Rachel A.
    Pluard, Timothy
    Nangia, Julie
    Lu, Janice
    Valdez-Albini, Frances
    Cobleigh, Melody
    Jones, Jason
    Lin, Nancy U.
    Winer, Eric
    Marcom, P. Kelly
    Thomas, Shana
    Anderson, Jill
    Haas, Brittney
    Hamann, Kimberly M.
    Bryce, Richard
    Lalani, Alshad S.
    Carey, Lisa
    Goetz, Matthew
    Gao, Feng
    Kimmick, Gretchen
    Pegram, Mark
    Ellis, Matthew J.
    Bose, Ron
    CANCER RESEARCH, 2021, 81 (13)
  • [10] Neratinib plus fulvestrant plus trastuzumab for hormone receptor-positive, HER2-mutant metastatic breast cancer and neratinib plus trastuzumab for triple-negative disease: Latest updates from the SUMMIT trial
    Jhaveri, Komal
    Park, Haeseong
    Waisman, James
    Goldman, Jonathan W.
    Guerrero-Zotano, Angel
    Boni, Valentina
    Haley, Barbara
    Mayer, Ingrid A.
    Brufsky, Adam
    Yang, Eddy S.
    Garcia-Saenz, Jose A.
    Bidard, Francois-Clement
    Crown, John
    Zhang, Bo
    Frazier, Aimee
    Diala, Irmina
    Eli, Lisa D.
    Barnett, Brian
    Wildiers, Hans
    CANCER RESEARCH, 2022, 82 (04)
12345